Heart drug carvedilol may slow Parkinson's progression
NCT ID NCT04218968
First seen Mar 11, 2026 · Last updated Jun 22, 2026 · Updated 17 times
Summary
This study tests whether carvedilol, a drug used for heart conditions, can slow the progression of Parkinson's disease in people with early warning signs like REM sleep behavior disorder. Fifteen participants will take carvedilol and have brain scans every six months for three years. The goal is to see if the drug preserves dopamine-producing cells and delays the onset of Parkinson's symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REM SLEEP BEHAVIOR DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Michele L Lima Gregorio
Los Angeles, California, 90046, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Carvedilol
What this could lead to
If it works, this could point toward a treatment that slows Parkinson's disease progression in its earliest stages.
What could go wrong
This is a very small, early-phase study with only 15 participants. It may not show a clear benefit, and carvedilol could have side effects like low blood pressure or fatigue.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.